[(3R)-1-[[6-[[3-[[(3R)-3-decanoyloxydodecanoyl]amino]-5-formyloxy-6-(hydroxymethyl)-4-[(3R)-3-tetradecanoyloxydodecanoyl]oxyoxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [(3R)-1-[[6-[[3-[[(3R)-3-decanoyloxydodecanoyl]amino]-5-formyloxy-6-(hydroxymethyl)-4-[(3R)-3-tetradecanoyloxydodecanoyl]oxyoxan-2-yl]oxymethyl]-2,4,5-trihydroxyoxan-3-yl]amino]-1-oxotetradecan-3-yl] hexadecanoate
• 化学式: C₉₁H₁₆₈N₂O₁₉
• 分子量: 1594.3
• InChiKey: XNFDLXYIVQDRHH-LILVOBQGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  27.8
• 重原子数：
  112
• 可旋转键数：
  82
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  298
• 氢给体数：
  6
• 氢受体数：
  19

文献信息

• INFLUENZA VACCINES INCLUDING COMBINATIONS OF PARTICULATE ADJUVANTS AND IMMUNOPOTENTIATORS
  申请人：NOVARTIS VACCINES AND DIAGNOSTICS SRL

  公开号：US20140248312A1

  公开（公告）日：2014-09-04

  Influenza vaccines containing insoluble particulate adjuvants have been found to elicit an IgG response that is primarily a TH2 response (IgG1). This response can be shifted towards a TH1 response (IgG2a) by including immunopotentiators in the compositions. Thus the invention provides an immunogenic composition comprising: (i) an influenza virus antigen; (ii) an insoluble particulate adjuvant; and (iii) a immunopotentiator.